33 completed, 16 unknown, 2 active not recruiting, 2 recruiting. 20 Phase 2, 19 Phase 3, 9 Phase 1, 5 Phase 4, 3 Not applicable.
Follow ChAdOx1 nCoV-19: new trials by email Literature Review of ChAdOx1 nCoV-19 trials Research Report on ChAdOx1 nCoV-19
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of COVID-19 Vaccines Given as a Booster in Healthy Adults in Indonesia (MIACoV Indonesia) Pfizer-BioNTech Standard dose, AstraZeneca Standard dose, Pfizer-BioNTech Fractional dose - COVID-19 | Phase 3 | Withdrawn | Murdoch Childrens Research Institute | 2024-04-01 | 2024-03-22 | |
| Immunogenicity of COVID-19 Vaccines in Tuberculosis Patients Pfizer-BioNTech COVID-19 vaccine, AstraZeneca vaccine, Janssen Ad26.COV2.S COVID-19 vaccine - Covid-19 Pandemics, Tuberculosis | Recruiting | University of Oxford | 133 | 2023-04-15 | 2026-04-13 | |
| Booster Superiority Study of PTX-COVID19-B Compared to Vaxzevria® in Adults Aged 18 Years and Older PTX-COVID19-B, Vaxzevria® - SARS-CoV-2 Infection | Phase 3 | Unknown | Everest Medicines (Singapore) Pte. Ltd. | 450 | 2023-02-03 | 2022-09-09 |
| Phase II/III Study of the AVX/COVID-12 Vaccine Against COVID-19 Applied as a Booster. AVX-COVID/12, ChAdOx-1-S[recombinant] - SARS-CoV-2 Infection | Phase 2 / Phase 3 | Completed | Laboratorio Avi-Mex, S.A. de C.V. | 4065 | 2022-11-09 | 2025-10-02 |
| A Phase III Study of COVID-19 Vaccine EuCorVac-19 in Healthy Adults EuCorVac-19, ChAdOx1 nCoV-19 - COVID-19 | Phase 3 | Completed | EuBiologics Co.,Ltd | 2600 | 2022-10-01 | 2024-06-17 |
| A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 in Adults Aged 18 Years and Above MVC-COV1901, AZD1222 - COVID-19 Vaccine | Phase 3 | Completed | Medigen Vaccine Biologics Corp. | 250 | 2022-07-30 | 2023-10-23 |
| Effectiveness of the Oxford-AstraZeneca COVID-19 Vaccine as a 2nd Booster, the REFORCO-Brazil Study ChAdOx1 nCOV-19 vaccine (Vaxzeria), BNT162b2 (Pfizer), Ad26.COV2.S (Janssen) - COVID-19 | Completed | AstraZeneca | 188814085 | 2022-07-22 | 2024-11-21 | |
| A Phase III of COVID-19 Vaccine EuCorVac-19 in Healthy Adults Aged 18 Years and Older EuCorVac-19, ChAdOx1 nCoV-19 - COVID-19 | Phase 3 | Completed | EuBiologics Co.,Ltd | 2852 | 2022-07-11 | 2025-01-07 |
| A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Vaccine Compared With AZD1222 MVC-COV1901, AZD1222 - COVID-19 Vaccine | Phase 3 | Completed | Medigen Vaccine Biologics Corp. | 200 | 2022-07-09 | 2023-10-23 |
| Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase 4 Dose-optimizing Trial Sinovac, AZD1222, BNT162b2 - COVID-19 | Phase 4 | Completed | Albert B. Sabin Vaccine Institute | 2354 | 2022-07-05 | 2024-01-30 |
| Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults Candidate vaccine, SCB-2019, Comirnaty Vaccine, Vaxzevria Vaccine - COVID-19 | Phase 3 | Completed | Clover Biopharmaceuticals AUS Pty | 1831 | 2022-06-13 | 2023-08-24 |
| Effectiveness, Immunogenicity and Safety of the Second Booster Dose of the Vaccine Against COVID-19 in the Elderly ChAdOx1 nCoV-19 or Comirnaty or Janssen COVID-19 Vaccine - COVID-19, Vaccine Adverse Reaction | Completed | Federal University of Espirito Santo | 260 | 2022-03-19 | 2026-03-23 | |
| Phase 3 Study to Evaluate Immunogenicity and Safety of BBV154 Booster Dose BBV154 Intranasal Vaccine, Intramuscular vaccine COVAXIN, Covishield - COVID-19 Respiratory Infection | Phase 3 | Completed | Bharat Biotech International Limited | 875 | 2022-02-26 | 2022-10-05 |
| EU Secondary Data Post-Authorisation Safety Study of AZD1222 AZD1222 - COVID-19, Vaccine Adverse Events of Special Interest | Completed | AstraZeneca | 5321930 | 2022-02-18 | 2025-01-28 | |
| A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults AZD1222 - COVID-19, SARS-CoV-2 | Phase 4 | Terminated | AstraZeneca | 34 | 2022-01-31 | 2025-01-27 |
| A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19 Half dose of MVC-COV1901, Full dose of MVC-COV1901, AZD1222 - COVID-19 Vaccine | Phase 2 | Completed | Medigen Vaccine Biologics Corp. | 804 | 2022-01-22 | 2023-03-15 |
| A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in Adults MVC-COV1901, AZD1222 - Covid19 Vaccine | Phase 3 | Completed | Medigen Vaccine Biologics Corp. | 1030 | 2021-10-08 | 2022-09-30 |
| Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19 AZD1222, rAd26-S - COVID-19 | Phase 1 / Phase 2 | Completed | R-Pharm | 100 | 2021-09-15 | 2022-06-03 |
| Immunogenicity of COVID-19 Vaccine on Heterologous Schedule Heterologous prime-boost schedule with AZD1222 and MVC-COV1901, Homologous prime-boost schedule with two doses of AZD1222 - Covid-19, Vaccine | Phase 2 | Completed | Chang Gung Memorial Hospital | 100 | 2021-09-15 | 2026-06-15 |
| Incidence of COVID-19 Following Vaccination in Botswana Against SARS CoV 2 AZD 1222 - COVID-19 | Phase 3 | Completed | Botswana Harvard AIDS Institute Partnership | 10888 | 2021-09-15 | 2023-02-08 |
Showing 20 of 56. Sign in to see all of them.
COVID-19 (39) · Coronavirus Infections (7) · Lung Diseases (2) · Respiration Disorders (2) · Down Syndrome (1) · Drug-Related Side Effects and Adverse Reactions (1) · Inflammatory Bowel Diseases (1) · Influenza, Human (1) · Liver Cirrhosis (1) · Long Term Adverse Effects (1) · Pneumonia (1) · Pneumonia, Viral (1) · Rheumatic Diseases (1) · Tuberculosis (1) · Vaccine-Preventable Diseases (1)
AstraZeneca (7) · University of Oxford (6) · Medigen Vaccine Biologics Corp. (4) · Federal University of Espirito Santo (3) · Ministerio de Salud de Ciudad Autónoma de Buenos Aires (3) · R-Pharm (3) · EuBiologics Co.,Ltd (2) · Ain Shams University (1) · Albert B. Sabin Vaccine Institute (1) · Assiut University (1) · Bharat Biotech International Limited (1) · Botswana Harvard AIDS Institute Partnership (1) · Canadian Immunization Research Network (1) · Chang Gung Memorial Hospital (1) · Clover Biopharmaceuticals AUS Pty (1)
Brazil (7) · United Kingdom (7) · Argentina (3) · Germany (3) · Russia (3) · Taiwan (3) · Thailand (3) · United States (3) · Canada (2) · Egypt (2) · India (2) · Mexico (2) · Netherlands (2) · Paraguay (2) · Philippines (2)
Andrew Pollard, Prof (3) · Mikhail Samsonov (3) · Allen Lien, MD. Dr.PH (2) · Adam Kucharski, MMath, PhD (1) · Alexander Douglas, Dr (1) · Allen Lien, MD. DrPH (1) · Ann Falsey, MD (1) · Annette Fox, PhD (1) · Cristina Rebordosa, MD, PhD (1) · Dorothee von Laer, MD (1) · Dr A Venkateshwar Rao, MBBS,MD (1) · Dr Ajeet Pratap Singh, MBBS,MD (1) · Dr Amit Suresh Bhate, MBBS,MD (1) · Dr Anil Kumar Pandey, MBBS,MD (1)
PMID 33306989, PMID 33617777, PMID 34480858, PMID 30679336, PMID 30936830, PMID 32702298, PMID 33220855, PMID 33335322, PMID 33335323, PMID 33725432, PMID 33798499, PMID 34153264, PMID 34360156, PMID 34416193, PMID 34587382, PMID 34688944, PMID 35192543, PMID 35305895, PMID 35574651, PMID 35617826, PMID 35748853, PMID 36075233, PMID 36106642, PMID 36115850, PMID 36127228, PMID 36273491, PMID 36309347, PMID 36435633, PMID 36610390, PMID 36713413, PMID 36851662, PMID 37080829, PMID 37115976, PMID 37138460, PMID 37149443, PMID 37271703, PMID 37385888, PMID 37406777, PMID 37439701, PMID 37783221, PMID 37903679, PMID 38643547, PMID 38827749, PMID 38878794, PMID 39019657, PMID 39225478, PMID 39318203, PMID 39675209, PMID 40068393, PMID 40620571